SEC Tracker
Get the app

THC Therapeutics

THC Therapeutics Q3 FY23: revenue $0

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers THC Therapeutics reported for Q3 FY23, the quarter ended Apr 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0Against $0 in Q3 FY2210-Q income statement, on EDGAR
  2. Net income$94KAgainst −$632K in Q3 FY2210-Q income statement, on EDGAR
  3. Cash and cash equivalents$15−100% from $4K in Q3 FY2210-Q balance sheet, on EDGAR
  4. Cash from operations−$2KAgainst −$98K in Q3 FY2210-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

View on EDGAR

Open in the app

Get an email when THC Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3523 and related industry codes: the same peer list as the financial tables.

  1. Nature's Miracle Holding NMHI public float $519K, Jun 30, 2025
  2. Arts Way Manufacturing ARTW public float $4M, May 31, 2025
  3. Lindsay LNN public float $1.4B, Feb 28, 2026
  4. Alamo Group ALG public float $2.2B, Jun 30, 2025
  5. Agco AGCO public float $6.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.